NCT02225704已完成2 期
A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 8
- 主要终点
- To determine safety
研究概览
简要总结
This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained prior to any study-related procedures
- •Age ≥18 years and male.
- •ECOG performance status ≤
- •Histologically/cytologically confirmed adenocarcinoma of the prostate, and without neuroendocrine differentiation or small cell histology.
- •Metastatic disease as confirmed by Computed tomography (CT)/ Magnetic resonance imaging (MRI) or bone scan.
- •6. Patients must have documented Progressive disease (PD) either by radiographic or PSA criteria as defined in a) and b) below:
- •For the Radiographic PD assessment, 2 sets of scans using the same imaging modality (ie CT/MRI or bone scan) and taken at separate time points are required to document radiographic disease progression during or following the patient's most recent anti-neoplastic therapy, (note: the 1st bone scan can be from before most recent therapy but the 2nd scan must show disease progression during or after the most recent therapy).
- •For patients with bone disease, progression will be assessed following recommendations by the Prostate Cancer Working Group (PCWG2, see Appendix FC): appearance of 2 or more new lesions on bone scan, confirmed, if necessary, by other imaging modalities (such as CT scan or MRI), if results of the bone scans are ambiguous).
- •For patients with soft tissue lesions progression will be assessed using RECIST 1.1 criteria, (see Appendix GD). Patients may have measurable or non-measurable disease according to RECIST criteria version 1.1 (see Appendix GD)
- •PSA progression is defined as an increase in PSA, as determined by 2 separate measurements taken at least 1 week apart and confirmed by a third. If the third measurement is not greater than the second measurement, then a fourth measurement must be taken and must be greater than the second measurement for the patient to be eligible for the study. Furthermore, the confirmatory PSA measurement (i.e. the third or, if applicable, fourth PSA measurement) must be defined. If a patient has received prior anti-androgen therapy (e.g. bicalutamide), PSA progression must be evident and documented after discontinuation of anti-androgen therapy, (note: The 1st PSA reading taken to document disease progression when the patient presents can be while the patient is on Casodex or other ADT).
- •Prior surgical castration or concurrent use of an agent for medical castration with testosterone at screening less than 50ng/dL.
- •Screening PSA ≥ 2 ng/mL.
- •Patients, even if surgically sterilized who (i.e. status post-vasectomy):
- •will abstain from intercourse
- •or must agree to use barrier contraception during and for 6 months after discontinuation of study treatment.
- •If the patient engages in sexual intercourse with a woman of childbearing potential, a condom and another form of birth control must be used during and for 6 months after treatment.
- •Stable medical condition
- •Life expectancy of 12 months or more based on general health and prostate cancer disease status as judged by the investigator.
- •Documented presence of osseous metastases with or without visceral involvement / lymph nodes.
- •Able to swallow study drug as whole tablet.
- •Adequate haematological, hepatic, and renal function.
- •Continuous daily use of oral prednisone, oral dexamethasone, or other systemic corticosteroids is allowed prior to study entry but must be discontinued a minimum of 2 weeks prior to start of study treatment.
排除标准
- •Patients should not be receiving any other investigational agents (within 30 days prior to registration)
- •Patients with Gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g. Crohn's disease, ulcerative colitis).
- •Have current active hepatic or biliary disease
- •Prior therapy with orteronel, ketoconazole, aminoglutethimide, abiraterone or enzalutamide
- •All anti-androgen therapy (including bicalutamide) is excluded within 6 weeks prior to first dose of study drug. Any other therapies for prostate cancer, other than GnRH analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol), or 5-alpha reductase inhibitors (eg, finasteride or dutasteride), must be discontinued 2 weeks before the first dose of study drug. [Bisphosphonates and Denosumab are allowed concomitant medications].
- •Prior chemotherapy for prostate cancer with the exception of:
- •neoadjuvant/ adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years prior to screening.
- •Patients who received prior docetaxol for castrate sensitive metastatic prostate cancer commencing with 120 days of ADT initation where total dose received did not exceed 450mg/m2
- •Prior exposure to bone directed radioisotope therapy, eg samarium 153, strontium 90;
- •Exposure to external beam radiation within 4 weeks prior to receiving the first dose of study drug. In patients with untreated imminent or established spinal cord compression, treatment with standard of care, as clinically indicated, should be completed before starting treatment with Ra-223 dichloride (Xofigo®).
- •Diagnosis of or treatment for another systemic malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.
- •History of myocardial infarction, unstable symptomatic ischemic heart disease/ unstable angina, uncontrolled on-going arrhythmias of Grade >2 , pulmonary embolism, or any other cardiac condition within 6 months prior to first dose of study drug.
- •New York Heart Association Class III or IV heart failure.
- •History of seizure, underlying brain injury with loss of consciousness, stroke, transient ischaemic attack (TIA), cerebral vascular accident, primary brain tumours or brain metastases, brain arteriovenous malformation, alcoholism., or the use of concomitant medications that may lower the seizure threshold.
- •Known human immunodeficiency virus (HIV) infection, active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any ongoing serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study. Patients will be tested for hepatitis B or C or HIV infection during screening if they are considered by the investigator to be at higher risk for these infections and have not been previously tested, or if testing is required by the independent ethics committee or institutional review board.
- •Prohibited medications, including drugs that may affect exposure to enzalutamide i.e. study drugs that induce or inhibit CYP3A4, CYP2C8, and CYP2C9
研究组 & 干预措施
Radium-223 and enzalutamide
Experimental
Radium-223 50kBq/kg by intravenous injection on day 1 of every 4 week cycle for maximum of 6 cycles Enzalutamide 160mg orally daily
干预措施: Radium-223 and enzalutamide (Drug)
结局指标
主要结局
To determine safety
时间窗: approximately 6 to 9 months
To record the incidence of grade 3 or higher adverse events during the period of combination therapy; graded according to the NCI CTCAE version 4
次要结局
- Time to clinical and Prostate Specific Antigen (PSA) progression(Approximately 2 years)
- PSA response(approximately 2 years)
- Time to first skeletal-related event(approximately 2 years)
- Pain assessment(approximately 6 - 9 months)
- Measure overall survival(approximately 2 years)
研究者
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
1 期
Radium-223 & Enzalutamide metastatic prostate cancer studyEUCTR2013-004850-97-IECancer Trials Ireland44
已完成
不适用
The study of combination therapy with radium-223 and enzalutamide in Osaka City UniversityCastration-resistant prostate cancer with bone metastasesJPRN-UMIN000029422Osaka City University Graduate School of Medicine10
Unknown
2 期
Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)Prostate CarcinomaNCT02484339University Hospital Freiburg274
Unknown
2 期
The Combination Therapy With Ra-223 and EnzalutamideCastration-resistant Prostate CancerBone MetastasesNCT03305224Taro Iguchi, MD, PHD10
已完成
2 期
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the BoneProstatic NeoplasmsNCT02023697Bayer391